Bris­tol-My­er­s' check­point com­bo scores in PhI­II study; As­traZeneca hands Cir­cas­sia pos­i­tive da­ta for COPD drug; Wood­ford apol­o­gizes again

⇨ Bris­tol-My­ers Squibb did get some good news on the check­point front to­day. The com­pa­ny says that their com­bi­na­tion of Op­di­vo and Yer­voy scored good re­sults for over­all sur­vival in ad­vanced re­nal cell car­ci­no­ma in their Check­Mate -214 study, com­par­ing their com­bo to suni­tinib. An­a­lysts say the good re­sults for two es­tab­lished drugs is like­ly to trig­ger a quick OK from reg­u­la­tors.

⇨ The UK’s Cir­cas­sia got a new lease on life af­ter the col­lapse of its failed al­ler­gy meds when it li­censed Du­ak­lir and Tu­dorza from As­traZeneca. And now the phar­ma gi­ant is hand­ing over pos­i­tive re­sults from a COPD study that the biotech be­lieves will open the door to a valu­able US mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA